FDA rescinds hydroxychloroquine emergency use authorization

The FDA has withdrawn its emergency use authorizations for malaria drug hydroxychloroquine and related drug chloroquine, according to a June 15 letter from the agency.

The agency granted emergency use authorization to the two drugs March 28 for treatment of patients with COVID-19. However, the FDA has concluded the drugs should not be prescribed outside clinical trials because research has not proven them to be an effective preventive or therapeutic treatment for the disease.

The FDA's letter details "it is no longer reasonable to believe that oral formulations of [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks."

The letter came as a response to the Biomedical Advanced Research and Development Authority's request to revoke the authorizations.

More articles on pharmacy:
States sue 26 generic drugmakers, accused of fixing prices since 2016
Virginia pharmacist pleads guilty to federal drug fraud
Pharmacists will push flu shots this fall amid potential second wave of COVID-19

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers